In immune checkpoint blockade (ICB)-resistant non-small cell lung cancer (NSCLC), PU.1 and Flt3 expression are reduced, leading to inhibited differentiation of classical Ly6C+ monocytes into DCs/TAMs [45]. Here, FLT3 is linked to non-small cell lung carcinoma.